Katherine A. Kelly BSa, Leah Edenfield PharmDb, Mary Beth Seegars MDb, Rakhee Vaidya MBBSb, Steven R. Feldman MD, PhDa,c,d,e, Lindsay C. Strowd MDa
aCenter for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC bDepartment of Internal Medicine, Section on Hematology/Oncology, Wake Forest School of Medicine, Winston-Salem, NC cDepartment of Pathology, Wake Forest School of Medicine, Winston-Salem, NC
dDepartment of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC
eDepartment of Dermatology, University of Southern Denmark, Odense, Denmark
Abstract
Background: Brentuximab vedotin (BV) is an anti-CD30 monoclonal antibody that appears to be more effective against CD30-expressing cutaneous T-cell lymphoma (CTCL) compared to current standard-of-care treatments.
Objective: To determine the real-world efficacy and adverse effects of BV use in patients with mycosis fungoides (MF) who were treated with BV at Atrium Health Wake Forest Baptist Medical Center.
Methods: Study staff performed a retrospective chart review of patients diagnosed with MF who were prescribed BV at Atrium Health Wake Forest Baptist Comprehensive Cancer Center.
Results: Regardless of their response to BV, all patients in our cohort had higher CD30 positivity on subsequent biopsies compared to their initial skin biopsy.
Conclusions: Improved understanding of appropriate CD30 testing and evaluation will allow for quicker invention of patients with BV responsive CTCL.
Brentuximab vedotin (BV) is an anti-CD30 monoclonal antibody conjugated with monomethyl auristatin E by a protease-cleavable linker.1 CD30 has a variable association with other cutaneous T-cell malignancies including mycosis fungoides (MF) and sezary syndrome (SS), making it a potential target for therapy.2 In this study we performed a retrospective chart review of patients with MF who were treated with BV at Atrium Health Wake Forest Baptist Medical Center to determine real-world efficacy and safety of BV use in this patient population.
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our cookie policy | Continue
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.